History and Experience
Dr. Selam joined the DRC in 1986 to perform the first US pioneer studies on insulin implantable pumps. Since then more than 200 phase 1-4 diabetic studies have been performed, the majority in the fields of insulin and devices, oral medications, neuropathy and obesity.
The DRC investigators have published over 200 original research articles in the field of diabetes and related diseases, and are regular lecturers in the major Diabetes International meetings.
- Amgen
- Astellas
- BMS
- Biodel
- Dainippon
- Eisai
- Eli Lilly
- GSK
- Johnson&Johnson
- Mannkind
- Merck
|
- Mitsubishi
- Novartis
- NovoNordisk
- Parke Davis
- Pfizer
- Roche
- Sankyo
- Sanofi
- Schwarz
- Syrrx
- Takeda
|
- DPP4 inhibitors
- GLP1
- New insulin analogs
- anti-obesity agents
- inhaled insulin
- neuropathy pain
- neuropathy regeneration
- new insulin delivery devices
These are some of the investigational compounds under current or oncoming evaluation at the DRC:
- Aldose reductase inhibitor for mild to moderate diabetic neuropathy
- Ampa receptor antagonist for painful diabetic neuropathy
- CCR2 receptor antagonist for painful diabetic neuropathy
- Cannabinoid receptor antagonist for obesity in type 2 diabetes patients
- GLP1 analog to reduce obesity in type 2 diabetes
- Inhibitor of glucose renal transport for type 2 diabetes on single oral agent
- Long acting GLP1 analogue for type 2 diabetes uncontrolled by oral agents
- Neuroprotective compound for mild to moderate diabetic neuropathy
- Next generation insulin pen for type 1 and insulin treated type 2 diabetes
- Ultra fast acting insulin for type 1 and 2 diabetes
|
|
|
Call the DRC and request to speak to the PI directly — 714.734.7944
